Results 171 to 180 of about 283,567 (361)

Antihepatitis B Surface Antigen and Hepatitis C Antibodies among Pregnant Women in an Urban Area of Mwanza City, Tanzania. [PDF]

J Pregnancy, 2019
Chibwe E, Silago V, Kajoro E, Juma M, Mkumbo E, Minja CA, Mujuni F, Mshana SE, Mirambo MM.   +8 more
europepmc   +1 more source

DETECTION OF ANTIBODIES TO HEPATITIS C VIRUS (HCV) NS5 PROTEIN AND ANTIBODIES TO HCV IgM FOR PREDICTION OF INTERFERON THERAPY EFFI- CACY IN PATIENTS WITH CHRONIC HEPATITIS C

, 2005
В. М. Мицура, С. В. Жаворонок, Е. Л. Красавцев, A. P. Demtchilo, Alkhansa Alshabi, I. L. Pavlovich   +5 more
openalex   +2 more sources

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Characterization of three novel monoclonal antibodies against hepatitis C virus core protein [PDF]

, 1996
Darius Moradpour, Takaji Wakita, Katsutoshi Tokushige, Rolf I. Carlson, K. Krawczyński, Jack R. Wands   +5 more
openalex   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Prevalence Of Hepatitis C Antibodies In Healthy Blood Donors

Indian Journal of Community Medicine, 2002
Research question : What is the prevalence of hepatitis C virus infection in healthy blood donors? Objective: To screen the blood donors for HCV antibodies routinely. Study design: Cross- sectional. Setting: Deptt.
Gupta Nalini, Kumar Amarjit
doaj  

Clinical significance of anti-envelope (E2) antibody in acute hepatitis C after blood transfusion.

, 1995
Masakazu Kobayashi
openalex   +2 more sources

Hepatitis C Antibody Measurement [PDF]

, 2020
openaire   +1 more source

The Squalene Oil‐in‐Water Nanoemulsion Vaccine Carrier AddaVax Potentiates TLR‐Induced B‐Cell Responses

Cytometry Part A, EarlyView.
ABSTRACT For vaccination, the mechanisms of action of antigens and of immunostimulatory pathogen‐associated molecular pattern (PAMP) adjuvants are better understood than the roles of the depot, carrier, and other formulation‐related influences. Here, we carried out cytometric studies of vaccine formulations and the effect of adjuvant formulations on B ...
Egest J. Pone, Jiin Felgner, Jenny Hernandez‐Davies, D. Huw Davies   +3 more
wiley   +1 more source

Nanoparticles in microdroplets: Recent advances in microfluidic generators for producing functional microbeads

Droplet, EarlyView.
Functional hybrid microbeads with electrical, magnetic, and/or optical responsiveness have emerged as versatile platforms for biotechnology. This review highlights recent advances in microfluidic technologies for producing such microbeads, with a focus on incorporating functional nanoparticles in microdroplet systems.
  Bayinqiaoge, Chengchen Zhang, Shi‐Yang Tang   +2 more
wiley   +1 more source